Sep 08, 2020

TCR² Therapeutics to Participate in Two Upcoming Conferences in September

Aug 12, 2020

TCR² Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update

Aug 06, 2020

TCR² Therapeutics to Present at the Wedbush PacGrow Healthcare Conference

Jul 28, 2020

TCR² Therapeutics Announces Pricing of Public Offering of Common Stock

Jul 27, 2020

TCR² Therapeutics Announces Proposed Public Offering of Common Stock

Jul 26, 2020

TCR² Therapeutics Announces RECIST Responses with First TC-210 Dose Tested in Advanced Mesothelin-Expressing Solid Tumors

Jul 24, 2020

TCR² Therapeutics to Announce Interim Data from Phase 1/2 Clinical Trial of TC-210 in Mesothelin-Expressing Solid Tumors

Jun 17, 2020

TCR² Therapeutics to Present at the BMO Prescriptions for Success Healthcare Conference

May 27, 2020

TCR² Therapeutics Hires Key Business Development and Regulatory Affairs Cell Therapy Experts to Support Strategic Objectives

May 15, 2020

TCR² Therapeutics to Present Data on PD-1 Switch TRuC Enhancement at American Association for Cancer Research (AACR) Virtual Meeting 2020